American Renal Associates Holdings, Inc (NYSE:ARA) shares shot up 5.8% during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $16.40 and last traded at $15.40, with a volume of 914,817 shares traded. The stock had previously closed at $14.56.
The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.12 by $0.04. American Renal Associates Holdings had a positive return on equity of 18.25% and a negative net margin of 1.54%. The company had revenue of $185.99 million during the quarter, compared to the consensus estimate of $188.23 million. The firm’s revenue was up .2% compared to the same quarter last year.
Several research firms recently commented on ARA. Zacks Investment Research downgraded American Renal Associates Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Wells Fargo & Company upgraded American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a report on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $25.50.
Several large investors have recently added to or reduced their stakes in ARA. Endurant Capital Management LP purchased a new stake in American Renal Associates Holdings during the first quarter worth about $776,000. Atria Investments LLC purchased a new stake in American Renal Associates Holdings during the first quarter worth about $181,000. State Street Corp increased its stake in American Renal Associates Holdings by 6.0% in the fourth quarter. State Street Corp now owns 172,589 shares of the company’s stock worth $3,673,000 after buying an additional 9,745 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in American Renal Associates Holdings by 3.6% in the first quarter. TimesSquare Capital Management LLC now owns 1,209,550 shares of the company’s stock worth $20,417,000 after buying an additional 41,500 shares in the last quarter. Finally, Van Berkom & Associates Inc. purchased a new stake in American Renal Associates Holdings during the second quarter worth about $6,886,000. Institutional investors and hedge funds own 90.83% of the company’s stock.
The stock’s market capitalization is $441.12 million. The stock’s 50 day moving average price is $16.79 and its 200-day moving average price is $17.94.
WARNING: This news story was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/american-renal-associates-holdings-inc-nyseara-trading-up-5-8-after-earnings-beat-updated.html.
American Renal Associates Holdings Company Profile
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.